OLMAT CT 40

About

OLMAT CT 40 is a fixed-dose combination medication designed for the effective management of essential hypertension, combining the therapeutic benefits of Olmesartan medoxomil, an angiotensin II receptor blocker (ARB), and Hydrochlorothiazide, a thiazide diuretic. Olmesartan exerts its antihypertensive effect by selectively blocking the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release, which results in vasodilation and a reduction in blood pressure. Hydrochlorothiazide complements this action by inhibiting sodium and chloride reabsorption in the distal convoluted tubules of the kidneys, leading to increased excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance. This dual mechanism of action provides an additive antihypertensive effect, making OLMAT CT 40 particularly effective for patients whose blood pressure is not adequately controlled by either monotherapy alone. The combination offers enhanced efficacy and improved patient compliance compared to taking the two components separately.

Uses

• Treatment of essential hypertension.
• When monotherapy with an ARB or diuretic is insufficient.
• To achieve target blood pressure in resistant cases.
• Reduction of cardiovascular risk associated with hypertension.

Directions For Use

Take orally once daily, with or without food, as directed by your physician.

Benefits

• Effective and sustained blood pressure control.
• Combines two complementary mechanisms of action.
• Improved patient adherence with a single pill.
• Reduces fluid retention and swelling.
• Suitable for patients needing dual therapy.
• Lowers overall cardiovascular burden.

Side Effects

• Dizziness
• Headache
• Fatigue
• Nausea
• Diarrhea
• Hypotension
• Hyperkalemia (Olmesartan)
• Hypokalemia (Hydrochlorothiazide)
• Muscle cramps
• Increased urination
• Cough (less common)
• Rash

Safety Measures

• Alcohol - Limit alcohol intake as it can enhance the hypotensive effects and increase risk of dizziness.
• Pregnancy - Contraindicated during the second and third trimesters due to risk of fetal harm from Olmesartan.
• Breastfeeding - Not recommended; components may pass into breast milk and potentially harm the infant.
• Liver - Use with caution in patients with severe hepatic impairment; dosage adjustments may be necessary.
• Kidney - Use with caution in patients with severe renal impairment; monitor kidney function and electrolytes closely.
• Lung - Generally safe for use in patients with lung conditions; no specific contraindications related to lung function.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.